Daiwa Securities Group Inc. Has $10.34 Million Stock Holdings in Alnylam Pharmaceuticals, Inc. $ALNY

Daiwa Securities Group Inc. increased its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 67.8% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 25,999 shares of the biopharmaceutical company’s stock after purchasing an additional 10,503 shares during the period. Daiwa Securities Group Inc.’s holdings in Alnylam Pharmaceuticals were worth $10,339,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in the business. First Horizon Corp lifted its position in shares of Alnylam Pharmaceuticals by 20.7% during the 4th quarter. First Horizon Corp now owns 163 shares of the biopharmaceutical company’s stock worth $65,000 after purchasing an additional 28 shares during the last quarter. Yousif Capital Management LLC lifted its position in shares of Alnylam Pharmaceuticals by 1.8% during the 4th quarter. Yousif Capital Management LLC now owns 1,676 shares of the biopharmaceutical company’s stock worth $666,000 after purchasing an additional 29 shares during the last quarter. Bessemer Group Inc. lifted its position in shares of Alnylam Pharmaceuticals by 15.6% during the 3rd quarter. Bessemer Group Inc. now owns 222 shares of the biopharmaceutical company’s stock worth $101,000 after purchasing an additional 30 shares during the last quarter. Everpar Advisors LLC lifted its position in shares of Alnylam Pharmaceuticals by 6.3% during the 4th quarter. Everpar Advisors LLC now owns 620 shares of the biopharmaceutical company’s stock worth $247,000 after purchasing an additional 37 shares during the last quarter. Finally, Coldstream Capital Management Inc. lifted its position in shares of Alnylam Pharmaceuticals by 2.4% during the 3rd quarter. Coldstream Capital Management Inc. now owns 1,640 shares of the biopharmaceutical company’s stock worth $748,000 after purchasing an additional 38 shares during the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on ALNY shares. Royal Bank Of Canada cut their price objective on Alnylam Pharmaceuticals from $450.00 to $445.00 and set an “outperform” rating for the company in a research report on Friday, May 1st. Needham & Company LLC lowered their price target on Alnylam Pharmaceuticals from $529.00 to $510.00 and set a “buy” rating on the stock in a research note on Thursday, February 12th. Weiss Ratings upgraded Alnylam Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, May 4th. Bank of America restated a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Thursday, February 12th. Finally, Jefferies Financial Group restated a “hold” rating and set a $330.00 price target (down from $522.00) on shares of Alnylam Pharmaceuticals in a research note on Monday, March 16th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat, Alnylam Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $463.13.

Insider Activity at Alnylam Pharmaceuticals

In other news, Director David E. I. Pyott sold 3,830 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $299.18, for a total value of $1,145,859.40. Following the sale, the director directly owned 1,582 shares in the company, valued at approximately $473,302.76. This represents a 70.77% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Melissa Mclaughlin sold 2,286 shares of the company’s stock in a transaction that occurred on Monday, April 6th. The shares were sold at an average price of $330.42, for a total value of $755,340.12. Following the completion of the sale, the insider owned 9,443 shares in the company, valued at approximately $3,120,156.06. This represents a 19.49% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders sold 7,740 shares of company stock worth $2,420,214. Corporate insiders own 0.86% of the company’s stock.

Alnylam Pharmaceuticals Trading Down 0.2%

ALNY stock opened at $303.05 on Friday. Alnylam Pharmaceuticals, Inc. has a 1-year low of $283.10 and a 1-year high of $495.55. The firm has a market cap of $40.46 billion, a P/E ratio of 82.80 and a beta of 0.29. The business’s 50 day moving average is $307.66 and its 200-day moving average is $349.36. The company has a current ratio of 3.13, a quick ratio of 3.06 and a debt-to-equity ratio of 0.94.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share for the quarter, beating the consensus estimate of $0.87 by $1.12. Alnylam Pharmaceuticals had a return on equity of 85.76% and a net margin of 11.72%.The company had revenue of $1.17 billion for the quarter, compared to analyst estimates of $1.12 billion. During the same period in the prior year, the company posted ($0.44) EPS. The company’s revenue was up 96.4% compared to the same quarter last year. Equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post 7.47 earnings per share for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.